Ozmosi | HS-630 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

HS-630

Alternative Names: HS-630, HS 630, HS630
Clinical Status: Active
Latest Update: None
Latest Update Note: None

Product Description

Mechanisms of Action: HER2 Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Zhejiang Hisun Pharmaceutical Co., Ltd./Hisun Pharmaceutical (Hangzhou) Co., Ltd./Beijing Tianguangshi Biotechnology Co., Ltd.
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HS-630

Countries in Clinic: China

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Breast Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CTR20181755

 CTR20181755

P1

Recruiting

Breast Cancer

None

2025-04-29

Patient Enrollment|Treatments

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions